Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
Lantheus Holdings, Inc. announced that Paul Blanchfield, President, will present at the Leerink Partners Global Biopharma Conference 2024. The presentation will be available via live webcast on the Company's website.
03/05/2024 - 08:30 AM
BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March 12.
To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com . A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.
About Lantheus www.lantheus.com .
Contacts:
Melissa Downs
When will Paul Blanchfield present at the Leerink Partners Global Biopharma Conference 2024?
Paul Blanchfield will present at the conference on Tuesday, March 12 at 9:20 a.m. ET.
Where can I access the live webcast of the presentation?
You can access the live webcast on Lantheus Holdings, Inc.'s website at www.lantheus.com.
How long will the replay of the webcast be available?
The replay of the webcast will be available on the Company's website for at least 30 days following the live presentation.
LNTH Rankings
#2662 Ranked by Stock Gains
LNTH Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
North Billerica
About LNTH
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
